drugset
drugset / Trial / NCT07656415

A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)

NCT07656415 ↗

Phase 3 Not yet recruiting 159 enrolled Agios Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to determine the effect of mitapivat versus placebo on the need for transfusions in subjects with SCD.

Timeline

Start
2026-08
Primary completion
2029-08
Completion
2030-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitapivat Small molecule 100 mg Oral

Indications

sickle cell disease